 BACKGROUND/AIMS: investigate clinical significance serum Tu M2-PK CA19-9 detection diagnosis cholangiocarcinoma. METHODS: tumour markers (Tu M2-PK CA19-9) 115 patients cholangiocarcinoma, 85 patients benign disease 120 blood donors detected ELISA. RESULTS: levels serum Tu M2-PK CA19-9 markedly higher patients cholangiocarcinoma controls (P<0.05). Tu M2-PK showed sensitivity (84.2%) specificity (90%) CA19-9 (68.4%) (75%). CONCLUSIONS: Tu M2-PK may used valuable diagnosis marker cholangiocarcinoma.